Marie Dutreix is a biologist (Ph.D.), the Director of Research of CNRS, team leader in the Institut Curie, and cofounder of the company DNA Therapeutics. She is a specialist of genetic instability and the biological effects of radiation. She has developed new strategies to treat tumors resistant to radiotherapy/chemotherapy and discovered new DNA repair inhibitors (Dbait/AsiDNA). Her work extend from basic research on DNA repair mechanisms to clinical applications of the AsiDNA inhibitors, and the development of innovative protocols with high-dose rate FLASH irradiation. She is the co-coordinator of the Institute iNanoTheRad of the University Paris-Saclay, the GDR MI2B of CNRS, and past president of the Société Française du Cancer (2012–2017). She has received numerous prizes, with the most recent being the prize of the Academy of Science (2016). She was awarded Chevalier de l’ordre National du Mérite in 2013 and Chevalier de l’ordre de la légion d’honneur in 2017. She has penned 102 international publications and 12 patents.
Marie Dutreix is a biologist (Ph.D.), the Director of Research of CNRS, team leader in the Institut Curie, and cofounder of the company DNA Therapeutics. She is a specialist of genetic instability and the biological effects of radiation. She has developed new strategies to treat tumors resistant to radiotherapy/chemotherapy and discovered new DNA repair inhibitors (Dbait/AsiDNA). Her work extend from basic research on DNA repair mechanisms to clinical applications of the AsiDNA inhibitors, and the development of innovative protocols with high-dose rate FLASH irradiation. She is the co-coordinator of the Institute iNanoTheRad of the University Paris-Saclay, the GDR MI2B of CNRS, and past president of the Société Française du Cancer (2012–2017). She has received numerous prizes, with the most recent being the prize of the Academy of Science (2016). She was awarded Chevalier de l’ordre National du Mérite in 2013 and Chevalier de l’ordre de la légion d’honneur in 2017. She has penned 102 international publications and 12 patents.